✦ LIBER ✦

BICALUTAMIDE 150 MG IN ADDITION TO STANDARD CARE IN PATIENTS WITH LOCALIZED OR LOCALLY ADVANCED PROSTATE CANCER: RESULTS FROM THE SECOND ANALYSIS OF THE EARLY PROSTATE CANCER PROGRAM AT MEDIAN FOLLOWUP OF 5.4 YEARS

✍ Scribed by WIRTH, MANFRED P.; SEE, WILLIAM A.; McLEOD, DAVID G.; IVERSEN, PETER; MORRIS, TOM; CARROLL, KEVIN

Book ID: 122013243
Publisher: Lippincott Williams and Wilkins
Year: 2004
Tongue: English
Weight: 220 KB
Volume: 172
Category: Article
ISSN: 0022-5347
DOI: 10.1097/01.ju.0000140159.94703.80

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Antiandrogen monotherapy in patients wit

Antiandrogen monotherapy in patients with localized or locally advanced prostate cancer: final results from the bicalutamide Early Prostate Cancer programme at a median follow-up of 9.7 years

✍ Peter Iversen; David G. McLeod; William A. See; Thomas Morris; Jon Armstrong; Ma 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 404 KB

Antiandrogen monotherapy in patients wit

Antiandrogen monotherapy in patients with localized or locally advanced prostate cancer: final results from the bicalutamide Early Prostate Cancer programme at a median follow-up of 9.7years

✍ Kibel, A.S. 📂 Article 📅 2011 🏛 Elsevier Science ⚖ 46 KB

Bicalutamide as Immediate Therapy Either

Bicalutamide as Immediate Therapy Either Alone or as Adjuvant to Standard Care of Patients with Localized or Locally Advanced Prostate Cancer: First Analysis of the Early Prostate Cancer Program

✍ See, William A.; Wirth, Manfred P.; McLeod, David G.; Iversen, Peter; Klimberg, 📂 Article 📅 2002 🏛 Lippincott Williams and Wilkins 🌐 English ⚖ 461 KB

Bicalutamide (‘Casodex’) 150 mg as

Bicalutamide (‘Casodex’) 150 mg as adjuvant to radiotherapy in patients with localised or locally advanced prostate cancer: Results from the randomised Early Prostate Cancer Programme

✍ Chris J. Tyrrell; Heather Payne; William A. See; David G. McLeod; Manfred P. Wir 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 245 KB

PS2 Late breaking Adding bicalutamide 15

PS2 Late breaking Adding bicalutamide 150mg to standard care for localised or locally advanced prostate cancer: results from the largest hormonal therapy trial ever conducted in prostate cancer patients, at over 7 years' follow up

📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 54 KB

181 Bicalutamide (‘Casodex’) 150 mg as a

181 Bicalutamide (‘Casodex’) 150 mg as adjuvant to radical prostatectomy significantly increases progression-free survival in patients with early non-metastatic prostate cancer: Analysis at a median follow-up of 5.4 years

✍ M. Wirth; P. Iversen; D. McLeod; W. See; C. Morris; T. Morris; K. Carroll 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 237 KB